Company profile
Viking Therapeutics, Inc.
NASDAQ: VKTX · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenue
EA Score
69BFH 56DQ 89GM —SS 66
v0.1 · 55/100 weight · provisional
↑ filing timeliness, Altman-Z · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$359.6M
Employees
65
as of 2026-09-08
Market cap
$4.1B
as of 2026-09-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$359.6M-$359.6M2025
Operating income-$393.3M-$393.3M2025
Total assets$715.7M$715.7M2025
Liabilities$76.7M$76.7M2025
Equity$639.1M$639.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Viking Therapeutics, Inc.’s revenue?
Viking Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Scholar Rock Holding Corporation40DOruka Therapeutics, Inc.66BParabilis Medicines, Inc.——Amylyx Pharmaceuticals, Inc.51DDenali Therapeutics Inc.52DSELLAS Life Sciences Group, Inc.50DNeighbors
San Diego →Key facts
CEOBrian Lian
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: VKTX
Employees65
IPO date2015-04-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.